Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for ARO-MAPT in Tauopathies including Alzheimer’s disease. The expected timing is based on the latest available company guidance and may change.
9/10/25– Regulatory clearance requested to initiate Ph1/2a. 12/08/25– First subjects dosed. Initial data expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.